Database helps identify most effective drugs
Practice Paterns Science Inc., St. Louis, has developed PTE-Registry,™ a national comparative database designed to help pharmaceutical and biotechnology companies identify the drugs that produce more efficient treatment patterns with fewer side effects
Practice Patterns Science Inc., St. Louis, has developed PTE-Registry,⢠a national comparative database designed to help pharmaceutical and biotechnology companies identify the drugs that produce more efficient treatment patterns with fewer side effects.
Educational tool
The database can also be used as a benchmarking tool to help educate health care providers on more effective practice patterns in treating medical conditions.
It can identify reductions in total medical treatment charges, reductions in complications and side effects and, for acute illnesses, reductions in treatment duration.
For health care plans, the database is a resource for comparing one plan's physician network with those of other health plans.
The database uses "diagnostic cluster methodology," a process in which medical and pharmacy claims data are linked to produce a "patient treatment episode." These patient treatment episodes link all charges incurred in treating a patient's medical condition within a specific period of time.
Practice Patterns Science will make a limited summary of the data available to the health care market with the publication of a three-volume set from the database.
The series is called the PPS/GreenBook⢠and includes information about drug treatment for chronic diseases like asthma, diabetes, depression, seizure disorders and peptic ulcer disease.
In the future, Practice Patterns Science plans to expand the database to target Medicare-specific findings using Medicare risk-population data. PR
Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns
April 30th 2025Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
FDA Approves AbbVie’s Rinvoq as First Oral JAK Inhibitor for Giant Cell Arteritis
April 30th 2025AbbVie secures FDA approval for Rinvoq as the first oral Janus kinase inhibitor indicated for giant cell arteritis, expanding its immunology portfolio and signaling strategic growth opportunities in underserved autoimmune markets.
